Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Screened! Home
TrialNet News and Events
Type 1 Diabetes - TrialNet e-news - April 2010

< Return to TrialNet E-News Main

TrialNet Reaches Important Milestone—screens 100,000 people for type 1 diabetes

Evan Wright

TrialNet has reached an important milestone: screening 100,000 people. This is a major achievement because it has helped researchers better predict who will develop diabetes and when it will require treatment. Early detection is vital. It helps patients avoid a severe, life-threatening condition called diabetic ketoacidosis, makes it possible to avoid dangerous complications that can occur when diabetes goes undetected, and may also help the body make insulin for a longer period of time.

"We want to thank everyone who has helped us to reach this important milestone. Screening is the first step on the pathway to prevention and provides an important opportunity for interventions at an early stage." – Jay Skyler, M.D., TrialNet Chair

Funded by the National Institutes of Health (NIH), TrialNet screenings are provided free of charge to relatives of people with type 1 diabetes— whose chances of developing the disease are 15 times greater than those with no family history. Participants whose results signal an increased risk may be eligible for participation in prevention studies exploring new ways to combat the disease.

TrialNet researchers are currently conducting two prevention studies for at-risk relatives of people with type 1 diabetes:

  • The Anti-CD3 Prevention Study is testing whether an experimental drug called teplizumab can prevent or delay type 1 diabetes. In previous studies, teplizumab helped preserve insulin production in newly diagnosed individuals

  • The Oral Insulin Prevention Study is testing whether one daily insulin capsule (taken by mouth) can prevent or delay type 1 diabetes. Results of an earlier study conducted by the Diabetes Prevention Trial-type 1 (the predecessor study group for TrialNet), suggested that oral insulin may delay type 1 diabetes for up to 10 years in individuals with higher levels of insulin autoantibodies.

“TrialNet is committed to going the distance to screen relatives of people with type 1 diabetes until we find a way to prevent this disease,” says Skyler. “If you haven’t been screened or know someone who might be interested, we invite you to get involved today.”

Nearly 200 TrialNet locations nationwide offer free screenings, and many conduct prevention studies. To learn more, visit www.DiabetesTrialNet.org or call 1-800-425-8361.

Join TrialNet in the fight against type 1 diabetes!

Here's how YOU can help:

  • If you have a relative with type 1 diabetes, find out if you are eligible for screening; if you are, get involved and get your family screened
  • Forward TrialNet E-News to family members and friends who might be interested
  • Tell your TrialNet Story by creating a video for TrialNet’s YouTube channel
  • Share this information on your MySpace or Facebook page
  • Follow TrialNet on Facebook and Twitter